Business and Operational Update

AI SummaryClose X

N4 Pharma plc provided a business and operational update highlighting progress in its collaboration with the University of Strathclyde on its Nuvec® gene delivery system, with in vitro and in vivo studies planned for early 2026. Latest studies indicate Nuvec® offers significant stability advantages over lipid nanoparticles, crucial for its oral anti-inflammatory product N4 101 and potential partnerships. Key 2025 achievements include successful preclinical demonstration of oral delivery and efficacy in an IBD animal model, and effective targeting of Nuvec® particles in both IBD and non-small cell lung cancer cells. The company anticipates further data readouts, including comparative performance data against lipid nanoparticles, in vivo biodistribution and targeting data, and a repeat in vivo study for N4 101. N4 Pharma has also strengthened its intellectual property with a PCT filing for its IBD program and a notice to allow a patent grant in Japan for improving viral vectors.

Disclaimer*

UK 100

Latest directors dealings